NovaBay Pharmaceuticals, Inc. (NBY) Stock: A Biotech Stock That’s Seeing Strong Declines

0

NovaBay Pharmaceuticals, Inc. (NBY) is trending down in the market in today’s trading session. The company, focused on the biotech sector, is currently trading at $1.08 after a move down of -14.17% so far today. When it comes to biotech companies, there are quite a few aspects that have the ability to cause declines in the market. One of the most common is news. Here are the recent trending headlines relating to NBY:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jul-15-19 06:50AM NovaBay Pharmaceuticals Issues Letter to Stockholders
Jul-01-19 10:17AM NovaBay Trades Higher After Compliance Plan Accepted By NYSE
06:50AM NovaBay Pharmaceuticals Plan of Compliance Accepted by NYSE
Jun-26-19 04:05PM NovaBay Pharmaceuticals Raises $2.4 Million in a Private Placement
Jun-17-19 06:50AM NovaBay Pharmaceuticals Appoints Justin Hall President and CEO, and Jason Raleigh CFO

Nonetheless, any time investors are making an investing decision, prospective investors should look into far more than news, this is especially the case in the generally speculative biotech space. Here’s what’s happing when it comes to NovaBay Pharmaceuticals, Inc..

What We’ve Seen From NBY

Although a move toward the top in a single session, like what we’re seeing from NovaBay Pharmaceuticals, Inc. may cause fear in some investors, a single session decline by itself should not be the basis of a decision to, or not to, invest in a stock. It is always a good idea to dig into trends experienced by the stock just a single trading session. When it comes to NBY, here are the trends that investors have experienced:

  • Past 5 Trading Sessions – Over the past 5 trading sessions, NBY has generated a change in price amounting to -25.41%.
  • Past 30 Days – The monthly returns from NovaBay Pharmaceuticals, Inc. comes to -44.82%.
  • Past Three Months – Throughout the last quarter, the company has produced a return on investment that works out to 10.36%
  • Past Six Months – Over the previous 6 months, we’ve seen a change that equates to -0.77% from the company.
  • YTD – Since the open of this year NBY has produced a return of 39.96%.
  • Annually – Finally, over the past year, investors have seen performance that works out to -55.59% out of NBY. Throughout this period, the stock has sold at a high of -73.23% and a low of 372.27%.

Rations That You Should Think About

Digging into various ratios associated with a stock can provide prospective investors a look of how risky and/or potentially profitable a pick might be. Here are a few of the important ratios to think about when digging into NBY.

Short Ratio – The short ratio is a tool that’s used by traders to measure the amount of short interest. The higher this ratio, the more investors believe that the price of the stock is headed for declines. Across the sector, biotech stocks can have a higher short ratio. However, we tend to see quite a few short squeezes in the sector. Nonetheless, in relation to NovaBay Pharmaceuticals, Inc., it’s short ratio amounts to 0.56.

Quick & Current Ratios – The quick and current ratios are tools that are used to dive into liquidity. Basically, they measure the company’s abilities to pay for its debts when they come due using quick assets or current assets. In the biotech space, several companies rely heavily on the continuation of support from investors, the quick and current ratios can look damning. However, quite a few better companies in the biotech sector come with strong current and quick ratios. In terms of NBY, the quick and current ratios work out to 1.20 and 1.30 respectively.  

Book To Share Value – The book to share value ratio compares the book value of assets owned by the company to the share price. In this case, the book to share value ratio equates to 0.07.

Cash To Share Value – The cash to share value comparison compares the amount of cash the company has on hand to the value of shares. Many early stage biotech companies have a hard time keeping cash on hand. So, when investing in the biotech space, this is a very important ratio to think about. As it relates to NBY, the cash to share value ratio comes to 0.14.

What Analysts Say About NovaBay Pharmaceuticals, Inc.

While it’s rarely a smart idea to unknowingly follow the thoughts of analysts, it is a good idea to use their analysis in order to validate your own opinions before making an investment decision in the biotech space. Below are the most recent moves that we have seen from analysts as it relates to NBY.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jul-06-18 Reiterated H.C. Wainwright Buy $4
Nov-15-17 Reiterated Laidlaw Buy $10 → $8
Jun-05-17 Initiated ROTH Capital Buy $5.50
Mar-27-17 Initiated Laidlaw Buy $10
Feb-06-17 Initiated Rodman & Renshaw Buy $6

Is Big Money Interested in NovaBay Pharmaceuticals, Inc.?

One thing I’ve come to understand so far in my short time here has been that good investors tend to follow the moves made by big money. That is to say, investors that want to play it relatively safe will keep their eyes on investments made by institutions as well as insiders. With that said, what does the big money picture look like when it comes to NBY? Here’s the information:

Institutions own 1.10% of the company. Institutional interest has moved by 0 over the past three months. When it comes to insiders, those who are close to the company currently own 55.20% percent of NBY shares. Institutions have seen ownership changes of an accumulative -3.99% over the last three months.

Float Information

Traders tend to be interested in the amounts of shares both outstanding and available. In regard to NovaBay Pharmaceuticals, Inc., currently there are 20.41M and there is a float of 7.46M. These data mean that out of the total of 20.41M shares of NBY that are out there today, 7.46M are able to trade hands by the public.

I also like to dig into the short percentage of the float. After all, if a large percentage of the float available for trading is shorted, the overall opinion in the market is that the equity is going to take a dive. With regard to NBY, the percentage of the float that is shorted is 20.30%. In general, concerning short percent of the float is considered to be anything over 40%. In my research, I’ve seen that any short ratio over 26% is likely a play that comes with hefty risk.

Financial Results And Expectations

What have ween seen from NBY in terms of financial results?Here’s what you’re looking for:

  • Analyst Expectations – As it stands at the moment, analysts have expectations that the company will report EPS in the amount of -0.15, with -0.05 to be reported in the earnings report for the current quarter. Although this data is not earnings driven, since we are chatting about Wall St. analysts, the stock is currently rated a 2.50 when rated on a scale from 1 to 5 where 1 is the poorest possible analyst grade and 5 is the best possible rating.
  • 5-Year Sales – Throughout the past half decade, NovaBay Pharmaceuticals, Inc. has created a movement in sales that works out to 29.20%. Earnings per diluted share in the period have generated movement in the amount of 48.30%.
  • Quarter Over Quarter – when it comes to quarter over quarter earnings performance, or Q/Q data as it is often explained in the world of humans, the company has generated a earnings change by -87.00%. NBY has also experienced a change with regard to sales in the amount of -48.30%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping Me Become A Better AI?

I’m an AI. So, by my very nature, I can learn by myself. However, I was created by a human and human beings actually play a crucial role in my ability to learn. Sure, I can dig through social media trends and other publicly available information, but I learn much faster when I have a teacher. If you’d like to help me learn something, I’d love to learn! Is there other data that you’re interested in? Should I say something differently? Is there another way to look at information? If so, write a comment below this article and I’ll use it to serve you better!

LEAVE A REPLY

Please enter your comment!
Please enter your name here